Payment overview · 2025
General Payments
$111.78
6 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel Lloyd Wegg, MD
Allopathic & Osteopathic Physicians|General Practice · WINCHESTER, IN · NPI 1013909241
Verified facts
What the public records show
CMS Open Payments records show Daniel Lloyd Wegg, MD received $111.78 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.63 | 40.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.98 | 28.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.05 | 16.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.12 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.78 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 177 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 130 |
| Lisinopril | Lisinopril | 477 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 74 |
| Losartan Potassium | Losartan Potassium | 318 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 282 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 68 |
| Gabapentin | Gabapentin | 253 | 54 |
| Metformin Hcl | Metformin Hcl | 240 | 55 |
| Omeprazole | Omeprazole | 227 | 55 |
| Potassium Chloride | Potassium Chloride | 183 | 44 |
| Furosemide | Furosemide | 166 | 34 |
| Trazodone Hcl | Trazodone Hcl | 164 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 31 |
| Eliquis | Apixaban | 134 | 23 |
| Buspirone Hcl | Buspirone Hcl | 129 | 24 |
| Alprazolam | Alprazolam | 120 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 36 |
| Allopurinol | Allopurinol | 112 | 24 |
| Sertraline Hcl | Sertraline Hcl | 112 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 30 |
| Indapamide | Indapamide | 105 | 24 |
| Carvedilol | Carvedilol | 103 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 29 |
| Lorazepam | Lorazepam | 98 | 22 |
| Spironolactone | Spironolactone | 97 | 21 |
| Alendronate Sodium | Alendronate Sodium | 92 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 26 |
| Metformin Hcl Er | Metformin Hcl | 85 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 16 |
| Prednisone | Prednisone | 80 | 35 |
| Donepezil Hcl | Donepezil Hcl | 79 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 14 |
| Famotidine | Famotidine | 70 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 16 |
| Cephalexin | Cephalexin | 66 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Lovastatin | Lovastatin | 65 | 17 |
| Clonazepam | Clonazepam | 64 | 11 |
| Pregabalin | Pregabalin | 63 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 18 |
| Jardiance | Empagliflozin | 61 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 14 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Glipizide Er | Glipizide | 57 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 13 |
| Montelukast Sodium | Montelukast Sodium | 56 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 13 |
| Ezetimibe | Ezetimibe | 53 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 11 |
| Simvastatin | Simvastatin | 52 | 14 |
| Atenolol | Atenolol | 51 | 15 |
| Aripiprazole | Aripiprazole | 50 | 12 |
| Tramadol Hcl | Tramadol Hcl | 50 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 48 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Linzess | Linaclotide | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 29 |
| Topiramate | Topiramate | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Finasteride | Finasteride | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Diazepam | Diazepam | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Morphine Sulfate | Morphine Sulfate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 22 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 24 |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nystatin | Nystatin | 27 | 14 |
| Telmisartan | Telmisartan | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 19 |
| Fluconazole | Fluconazole | 25 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Cholestyramine Light | Cholestyramine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Prochlorperazine Edisylate | Prochlorperazine Edisylate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.78 · 6 records | Novo Nordisk Inc | CAPLYTA, JOURNAVX, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error